Ferenc G Rick

List of Publications by Year in Descending Order

60 papers	1,540 citations	23 h-index	35 g-index
62 ext. papers	1,691 ext. citations	5.1 avg, IF	4.15 L-index

#	Paper	IF	Citations
60	A new approach to the treatment of acute myeloid leukaemia targeting the receptor for growth hormone-releasing hormone. *British Journal of Haematology*, **2018**, 181, 476-485	4.5	5
59	Growth hormone-releasing hormone antagonists reduce prostatic enlargement and inflammation in carrageenan-induced chronic prostatitis. *Prostate*, **2018**, 78, 970-980	4.2	22
58	Synthesis and structure-activity studies on novel analogs of human growth hormone releasing hormone (GHRH) with enhanced inhibitory activities on tumor growth. *Peptides*, **2017**, 89, 60-70	3.8	29
57	Antagonists of growth hormone-releasing hormone inhibit proliferation induced by inflammation in prostatic epithelial cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 1359-1364	11.5	22
56	Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. *Prostate*, **2017**, 77, 1036-1054	4.2	18
55	The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. *Urologic Oncology: Seminars and Original Investigations*, **2017**, 35, 183-191	2.8	44
54	Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 1895-900	11.5	9
53	Grade-dependent Response to Finasteride in Early Prostate Cancer. *EBioMedicine*, **2016**, 7, 13-4	8.8	
52	Potentiating effects of GHRH analogs on the response to chemotherapy. *Cell Cycle*, **2015**, 14, 699-704	4.7	8
51	Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. *Hormones and Cancer*, **2015**, 6, 100-6	5	4
50	New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones. *Asian Journal of Andrology*, **2015**, 17, 925-8	2.8	7
49	Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 270-4	2.8	23
48	Targeting the 5′AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 617-32	6.4	24
47	New therapeutic approach to heart failure due to myocardial infarction based on targeting growth hormone-releasing hormone receptor. *Oncotarget*, **2015**, 6, 9728-39	3.3	15
46	Androgens regulate prostate cancer cell growth via an AMPK-PGC-1□mediated metabolic switch. *Oncogene*, **2014**, 33, 5251-61	9.2	149
45	Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 1084-9	11.5	35
44	Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function. *Cell Cycle*, **2014**, 13, 2790-7	4.7	22

43	Protective effect of Growth Hormone-Releasing Hormone agonist in bacterial toxin-induced pulmonary barrier dysfunction. *Frontiers in Physiology*, **2014**, 5, 259	4.6	14
42	Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 781-6	11.5	10
41	Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities. *Peptides*, **2014**, 52, 104-12	3.8	44
40	Antagonistic analogs of growth hormone-releasing hormone increase the efficacy of treatment of triple negative breast cancer in nude mice with doxorubicin; A preclinical study. *Oncoscience*, **2014**, 1, 665-73	0.8	13
39	Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels. *Oncotarget*, **2014**, 5, 4567-78	3.3	22
38	Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. *World Journal of Gastroenterology*, **2014**, 20, 6102-12	5.6	44
37	Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro. *Targeted Oncology*, **2013**, 8, 281-90	5	13
36	Re: editorial comment on LHRH antagonist cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia (Prostate 2011; 71: 736-747). *Journal of Urology*, **2013**, 189, 1604-5	2.5	
35	Agonists of luteinizing hormone-releasing hormone in prostate cancer. *Expert Opinion on Pharmacotherapy*, **2013**, 14, 2237-47	4	19
34	Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental benign prostatic hyperplasia. *Prostate*, **2013**, 73, 873-83	4.2	21
33	Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs. *Toxins*, **2013**, 5, 1244-60	4.9	20
32	Hormonal manipulation of benign prostatic hyperplasia. *Current Opinion in Urology*, **2013**, 23, 17-24	2.8	15
31	Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 2617-22	11.5	22
30	Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. *Anti-Cancer Drugs*, **2013**, 24, 150-7	2.4	15
29	Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. *Oncology Reports*, **2013**, 30, 413-8	3.5	23
28	An update on the use of degarelix in the treatment of advanced hormone-dependent prostate cancer. *OncoTargets and Therapy*, **2013**, 6, 391-402	4.4	34
27	Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108. *Oncotarget*, **2013**, 4, 751-60	3.3	14
26	Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone. *Oncotarget*, **2013**, 4, 422-32	3.3	19

25	Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. *Journal of Urology*, **2012**, 187, 1498-504	2.5	30
24	Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. *Cell Cycle*, **2012**, 11, 2518-25	4.7	19
23	Antagonists of growth hormone releasing hormone (GHRH) given before whole body radiation lead to modulation of radiation response and organ-specific changes in the expression of angiogenesis. *Journal of Radiation Oncology*, **2012**, 1, 389-396	0.7	4
22	Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. *Prostate*, **2012**, 72, 555-65	4.2	26
21	Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 1655-60	11.5	54
20	Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI). *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 559-63	11.5	48
19	GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. *Cell Cycle*, **2012**, 11, 4203-10	4.7	17
18	Agonist of growth hormone-releasing hormone reduces pneumolysin-induced pulmonary permeability edema. *Proceedings of the National Academy of Sciences of the United States of America* , **2012**, 109, 2084-9	11.5	44
17	Beneficial effects of novel antagonists of GHRH in different models of Alzheimer‾s disease. *Aging*, **2012**, 4, 755-67	5.6	29
16	Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]. *Oncotarget*, **2012**, 3, 686-99	3.3	29
15	Antagonists of growth hormone-releasing hormone suppress in vivo tumor growth and gene expression in triple negative breast cancers. *Oncotarget*, **2012**, 3, 988-97	3.3	38
14	Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. *Anti-Cancer Drugs*, **2012**, 23, 906-13	2.4	5
13	The effect of a novel antagonist of growth hormone releasing hormone on cell proliferation and on the key cell signaling pathways in nine different breast cancer cell lines. *International Journal of Oncology*, **2011**, 39, 1025-32	4.4	11
12	LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. *Prostate*, **2011**, 71, 736-47	4.2	59
11	Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 3755-60	11.5	59
10	Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer. *Hormone and Metabolic Research*, **2011**, 43, 816-20	3.1	13
9	Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 2604-9	11.5	78
8	The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma. *Hormone and Metabolic Research*, **2010**, 42, 781-6	3.1	18

7	Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. *Cancer Letters*, **2010**, 294, 35-42	9.9	20
6	A correlation of endocrine and anticancer effects of some antagonists of GHRH. *Peptides*, **2010**, 31, 1839-46	3.46	21
5	GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. *Cell Cycle*, **2009**, 8, 3149-56	4.7	32
4	Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162. *Peptides*, **2009**, 30, 1643-50	3.8	15
3	Preclinical evaluation of properties of a new targeted cytotoxic somatostatin analog, AN-162 (AEZS-124), and its effects on tumor growth inhibition. *Anti-Cancer Drugs*, **2009**, 20, 553-8	2.4	17
2	Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138. *Prostate*, **2008**, 68, 1763-72	4.2	28
1	Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 14513-8	11.5	28